Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials. [electronic resource]
Producer: 20170418Description: e85-94 p. digitalISSN:- 2152-2669
- Antineoplastic Agents -- administration & dosage
- Disease Progression
- Female
- Fusion Proteins, bcr-abl -- genetics
- Humans
- Imatinib Mesylate -- administration & dosage
- Leukemia, Myeloid, Chronic-Phase -- diagnosis
- Male
- Mutation
- Odds Ratio
- Protein Kinase Inhibitors -- administration & dosage
- Publication Bias
- Randomized Controlled Trials as Topic
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; Systematic Review
There are no comments on this title.
Log in to your account to post a comment.